Biopharma clusters 21.1.2013

21
This project is funded by the European Union Integrated Innovation Support Programme Best Practice in Biopharma Clusters and Initiatives Dr. Yannis Pierrakis, 21 Jan 2013

Transcript of Biopharma clusters 21.1.2013

Page 1: Biopharma clusters 21.1.2013

This project is funded by

the European Union

Integrated Innovation Support

Programme

Best Practice in Biopharma Clusters and

Initiatives

Dr. Yannis Pierrakis, 21 Jan 2013

Page 2: Biopharma clusters 21.1.2013

This project is funded by

the European Union Structure of the presentation

• Current Trends on Biopharma Clusters

• Clusters, data and the internet

• Case study 1: OneNucleus – Cambridge

• Case study 2: Bavarian Biotechnology Cluster

• Common features within the success stories

– How do they operate?

– How do they secure finance?

• EBR Council of European BioRegions

• Useful links

2

Page 3: Biopharma clusters 21.1.2013

This project is funded by

the European Union Current Trends on Biopharma Clusters

• Companies and clusters form strategic alliances

– High uncertainty of product outcome and a heavy

reliance on R&D

– Companies are becoming increasingly unable to

conduct complete in-house R&D development

– We are seeing a growing number of strategic alliances

between pharmaceutical companies, biotechs,

academic centres and clusters

– 2800 European organisations are currenlty active in

the biopharmaceutical industry, 1050 are actively

engaging in strategic alliances with others (PharmaDeals 2006)

3

Page 4: Biopharma clusters 21.1.2013

This project is funded by

the European Union Current Trends on Biopharma Clusters

Integrated Innovation

Support Programme (IISP) 4

Source: PharmaDeals 2006

Page 5: Biopharma clusters 21.1.2013

This project is funded by

the European Union Leveraging efforts and resources

5

Page 6: Biopharma clusters 21.1.2013

This project is funded by

the European Union

Clusters, data and the internet

6

Page 7: Biopharma clusters 21.1.2013

This project is funded by

the European Union

Clusters, data and the internet

7

Page 8: Biopharma clusters 21.1.2013

This project is funded by

the European Union OneNucleus – Cambridge

8

- Not for profit organisation

- A large pool of companies to support

business-to-business interaction

- Membership provides discounted entry to

events in London and Cambridge

- Economies of scale supporting the

group’s purchasing scheme

- An expanded training programme

focused on the needs of members

- Investment pitches

- Well connected with Universities and VCs

Page 9: Biopharma clusters 21.1.2013

This project is funded by

the European Union OneNucleus – Cambridge

9

- Training courses (for managers and scientists,

50% subsidized for SMEs, innovation vouchers)

- Small Molecule Drug Discovery

- Introduction to Drug Development

- Introduction to Management

- Health and Safety for Representatives and

Managers

- Laboratory Health and Safety

- Commercial Awareness

- Scientific Presentation Skills

- BioProject Management

Page 10: Biopharma clusters 21.1.2013

This project is funded by

the European Union OneNucleus – Cambridge

10

- Services and activities

- Collaborates with Cambridge University to

allow its Members to attend a series of

lectures on Management of Technology and

Innovation

- Available lab space

- Equipment/items for sale (including auctions

from around the world)

- Relationships with US top clusters

- Participates in EU funded projects

- Collaboration with BioMunich

Page 11: Biopharma clusters 21.1.2013

This project is funded by

the European Union 5 Reasons why Cambridge is a Success

11

1. Most important has been the presence of

Cambridge University

2. Strong local industrial base has provided the

necessary general infrastructure

3. Provision of purpose-built bio-incubator

facilities

4. The entrepreneurial culture

5. The availability of venture capital funding

from London

Page 12: Biopharma clusters 21.1.2013

This project is funded by

the European Union Bavarian Biotechnology Cluster

• Cluster’s objectives:

– Development of an innovation culture from education

to economy

– Supporting connections within the biotechindustry

itself as well as between local biotech companies and

global players

– Strengthening ties between research institutions and

the industry

– Advice on finance opportunities and promotion

schemes and funding programs

– Representation at the international level

12

Page 13: Biopharma clusters 21.1.2013

This project is funded by

the European Union Bavarian Biotechnology Cluster

• Network Organisation and International Representation

– Development of synergy potentials and communicates

a uniform public presence

– Preparation of an annual Bavarian-wide Biotechnology

Report

– Establishment of an interactive B@B communication

portal for the networking between research and

industry

– Regular need-assessments for the regions's SMEs

13

Page 14: Biopharma clusters 21.1.2013

This project is funded by

the European Union Bavarian Biotechnology Cluster

• Scouting and Technology Transfer

– Targeted scouting activities enable the transfer of

innovative technologies from research institutions to

companies and provide active support for start-ups

– Active scouting for innovative research projects with

commercialisation potential

– Establishment of Cluster Scouting Groups composed

of experts from the academic community and the

industry

– Coaching and training

14

Page 15: Biopharma clusters 21.1.2013

This project is funded by

the European Union

Key driving forces of pharma/biotech

cluster

15

Page 16: Biopharma clusters 21.1.2013

This project is funded by

the European Union

Common features within the success

stories

• How do they operate?

– Active networking in order to facilitate access to

knowledge, funding and equipment

– Establish collaboration with universities and

incubators

– Organise training based on their member’s

needs

– Form purchasing consortia, which through bulk

buying reduces the cost of laboratory material

purchases

16

Page 17: Biopharma clusters 21.1.2013

This project is funded by

the European Union

Common features within the success

stories

• How do they operate?

– Facilitate access to VC funding

– Cluster promotion (attending trade

fairs/conferences, organising conferences,

partnering events with overseas companies,

presentations for local companies)

– Articulate needs/lobbying (interaction with local

government, interaction with national

government)

17

Page 18: Biopharma clusters 21.1.2013

This project is funded by

the European Union

Common features within the success

stories

• From where do cluster organisations finance their

activities?

– Provide training at a fee (not only to cluster

members but to all interested parties)

– Subscriptions (depends on the company size e.g.

in OneNucleus starts from £165)

– Receive sponsorships (large companies,

associations)

– Activation of already existing financing schemes

– Actively involve in EU funded projects

18

Page 19: Biopharma clusters 21.1.2013

This project is funded by

the European Union EBR Council of European BioRegions

• A self-financed network with over 50 biocommunities as

members across Europe and with links into clusters

around the globe (spun out from an FP6 project)

• Implementing cluster strategy

– A practical guide to developing and implementing a

cluster development strategy

• Raising visibility of cluster research facilities

– Provides examples of promotion at cluster and

individual facility level

19

Page 20: Biopharma clusters 21.1.2013

This project is funded by

the European Union EBR Council of European BioRegions

• Internationalisation services

– Sharing the internationalisation tools commonly in use

in clusters across Europe

• SME self assessment tools

– An invaluable collection of websites that cluster

managers can use to support their SMEs in business

development

• Support for cluster actors

– Another extensive website section, with examples of

how cluster managers support different parts of their

biocommunity, with a strong focus on SME

development

20

Page 21: Biopharma clusters 21.1.2013

This project is funded by

the European Union Useful links

• European Cluster Observatory

http://www.clusterobservatory.eu

• EBR Council of European BioRegions

http://www.cebr.net

• OneNucleus

http://www.onenucleus.com

• Cambridge Cluster Map

http://www.camclustermap.com

• Bavarian Biotechnology Cluster

http://www.biotech-bavaria.de

• Bio-Munich

http://www.bio-m.org/en

21